Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Merseburger

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Anticancer Research|January 30, 2003
p63 expression profile in normal and malignant prostate epithelial cellsLeland D Davis, Wei Zhang, Axel Merseburger, et al.
World Journal of Urology|March 13, 2012
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, et al.
Advances in Therapy|March 8, 2017
Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate CancerFabian Haupt, Georg Berding, Ali Namazian, et al.
BJU International|January 12, 2013
Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implantsAndreas Meyer, Julia Wassermann, Antje Warszawski-Baumann, et al.
Urologie (Heidelberg, Germany)|April 13, 2026
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus]Marc-Oliver Grimm, Christian Gratzke, Boris Hadaschik, et al.
World Journal of Urology|January 8, 2024
The landscape of penile cancer research in Germany and Austria: a survey among professors in academic centers holding chair positions and results of a literature searchSemih Sarcan, Ingmar Wolff, Lukas Lusuardi, et al.
Journal for Immunotherapy of Cancer|January 10, 2023
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitorsAristotelis Bamias, Axel Merseburger, Yohann Loriot, et al.
World Journal of Urology|October 5, 2011
XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrenceStefan Aufderklamm, Jörg Hennenlotter, Tilman Todenhoefer, et al.
European Urology Focus|May 16, 2025
Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysisMarcin Miszczyk, Tamás Fazekas, Paweł Rajwa, et al.
Oncotarget|December 16, 2016
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signalingAnne Offermann, Ignacija Vlasic, Isabella Syring, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Anticancer Research|January 30, 2003
p63 expression profile in normal and malignant prostate epithelial cellsLeland D Davis, Wei Zhang, Axel Merseburger, et al.
World Journal of Urology|March 13, 2012
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, et al.
Advances in Therapy|March 8, 2017
Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate CancerFabian Haupt, Georg Berding, Ali Namazian, et al.
BJU International|January 12, 2013
Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implantsAndreas Meyer, Julia Wassermann, Antje Warszawski-Baumann, et al.
Urologie (Heidelberg, Germany)|April 13, 2026
[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus]Marc-Oliver Grimm, Christian Gratzke, Boris Hadaschik, et al.
World Journal of Urology|January 8, 2024
The landscape of penile cancer research in Germany and Austria: a survey among professors in academic centers holding chair positions and results of a literature searchSemih Sarcan, Ingmar Wolff, Lukas Lusuardi, et al.
Journal for Immunotherapy of Cancer|January 10, 2023
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitorsAristotelis Bamias, Axel Merseburger, Yohann Loriot, et al.
World Journal of Urology|October 5, 2011
XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrenceStefan Aufderklamm, Jörg Hennenlotter, Tilman Todenhoefer, et al.
European Urology Focus|May 16, 2025
Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysisMarcin Miszczyk, Tamás Fazekas, Paweł Rajwa, et al.
Oncotarget|December 16, 2016
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signalingAnne Offermann, Ignacija Vlasic, Isabella Syring, et al.
Pageof 4